These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31932334)

  • 1. Defining the concept of fair pricing for medicines.
    Moon S; Mariat S; Kamae I; Pedersen HB
    BMJ; 2020 Jan; 368():l4726. PubMed ID: 31932334
    [No Abstract]   [Full Text] [Related]  

  • 2. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 3. New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines.
    Suleman F; Low M; Moon S; Morgan SG
    BMJ; 2020 Jan; 368():l4408. PubMed ID: 31932324
    [No Abstract]   [Full Text] [Related]  

  • 4. Pricing of pharmaceuticals is becoming a major challenge for health systems.
    Morgan SG; Bathula HS; Moon S
    BMJ; 2020 Jan; 368():l4627. PubMed ID: 31932289
    [No Abstract]   [Full Text] [Related]  

  • 5. Innovation-Innovation Tradeoffs in Drug Pricing.
    Sachs RE; Frakt AB
    Ann Intern Med; 2016 Dec; 165(12):871-872. PubMed ID: 27723887
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical pricing conundrum: time to get rid of it?
    Garattini L; Padula A
    Eur J Health Econ; 2018 Nov; 19(8):1035-1038. PubMed ID: 30030646
    [No Abstract]   [Full Text] [Related]  

  • 7. Pandora's Prescription: The Pharmaceutical Pricing
    Pederson T
    FASEB J; 2017 Nov; 31(11):4661-4662. PubMed ID: 29093000
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications.
    Huskamp HA; Shinogle JA
    Psychiatr Serv; 2005 Sep; 56(9):1056-8. PubMed ID: 16148317
    [No Abstract]   [Full Text] [Related]  

  • 9. Notable deals in the pharmaceutical industry in the fourth quarter of 2016.
    D'Souza P
    Drugs Today (Barc); 2017 Jan; 53(1):75-82. PubMed ID: 28387386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Economics of Indication-Based Drug Pricing.
    Chandra A; Garthwaite C
    N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
    [No Abstract]   [Full Text] [Related]  

  • 11. Improving access to vaccines through tiered pricing.
    Berkley S
    Lancet; 2014 Jun; 383(9936):2265-7. PubMed ID: 24636625
    [No Abstract]   [Full Text] [Related]  

  • 12. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines.
    Tetteh E
    Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829
    [No Abstract]   [Full Text] [Related]  

  • 14. Value-Based Pricing and Patient Access for Specialty Drugs.
    Robinson JC; Howell S; Pearson SD
    JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?
    Garattini L; Padula A
    J R Soc Med; 2020 Mar; 113(3):93-97. PubMed ID: 31858868
    [No Abstract]   [Full Text] [Related]  

  • 16. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability.
    Knox RP; Kesselheim AS; Sarpatwari A
    JAMA; 2022 May; 327(17):1647-1648. PubMed ID: 35426909
    [No Abstract]   [Full Text] [Related]  

  • 19. Indication-specific Drug Pricing - Simple in Theory, Complex in Reality.
    Kwon S
    Manag Care; 2018 May; 27(5):23-25. PubMed ID: 29763404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D.
    Schulthess D; Gassull D; Maisel S
    Ther Innov Regul Sci; 2019 Nov; 53(6):746-751. PubMed ID: 31771361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.